24/7 Market News Snapshot 07 August, 2025 – OS Therapies Incorporated (NYSE:OSTX)

August 7, 2025

DENVER, Colo., 07 August, 2025 (www.247marketnews.com) – (NYSE:OSTX) are discussed in this article.
OS Therapies Incorporated (OSTX), a clinical-stage biopharmaceutical company dedicated to innovative treatments for osteosarcoma and other solid tumors, has seen promising developments both in its stock performance and clinical trial results. As of today, the company opened at $1.74 and is currently trading at $1.83, demonstrating an approximate gain of 4.57%. With a notable volume of 1.91 million shares, there is robust investor interest, indicating positive sentiment and potential bullish momentum, especially as traders observe key resistance levels around $1.85 and support at $1.75.

The company’s recent announcement regarding interim results from its Phase 2b trial for OST-HER2, an off-the-shelf immunotherapy targeting recurrent pulmonary metastatic osteosarcoma, has contributed to this favorable market response. The trial reported that 66.6% of patients treated with OST-HER2 achieved an overall survival rate at the two-year mark, a significant increase compared to the historical control group’s rate of 40% (p = 0.0046). This breakthrough positions OST-HER2 as a critical contender in the biopharmaceutical landscape.

In addition, OS Therapies is preparing for a pivotal Biologics Licensing Application (BLA) submission following an upcoming End of Phase 2 Meeting with the U.S. Food and Drug Administration (FDA) on August 27, 2025. The company aims to streamline the approval process by engaging in discussions for Regenerative Medicine Advanced Therapy (RMAT) designation and Breakthrough Therapy designation (BTD), facilitating its advancement through the Accelerated Approval Program.

Furthermore, OS Therapies’ inclusion in the Russell Microcap, Russell Microcap Value, and Russell Microcap Growth indexes emphasizes its market potential and growth trajectory. With a deep commitment to enhancing patient outcomes for those affected by pulmonary metastatic osteosarcoma, OS Therapies remains poised to lead transformative advancements in oncology treatment.

Related news for (OSTX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.